{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T11:07:17Z","timestamp":1777547237227,"version":"3.51.4"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T00:00:00Z","timestamp":1738540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T00:00:00Z","timestamp":1738540800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100008318","name":"Asociaci\u00f3n Espa\u00f1ola para el Estudio del H\u00edgado","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008318","id-type":"DOI","asserted-by":"crossref"}]},{"name":"\u201cAjuts per a la iniciaci\u00f3 a la recerca 2022\u201d from Societat Catalana de Digestologia"},{"name":"Departament de Salut (Beca del Pla Estrat\u00e8gic de Recerca i Innovaci\u00f3 en Salut","award":["PERIS_IPIF19-SLT008\/18\/00182"],"award-info":[{"award-number":["PERIS_IPIF19-SLT008\/18\/00182"]}]},{"name":"Spanish Health Ministry"},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI20\/00609"],"award-info":[{"award-number":["PI20\/00609"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI18\/00542"],"award-info":[{"award-number":["PI18\/00542"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["FI19\/00222"],"award-info":[{"award-number":["FI19\/00222"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI13\/01229"],"award-info":[{"award-number":["PI13\/01229"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI18\/00768"],"award-info":[{"award-number":["PI18\/00768"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI18\/0358"],"award-info":[{"award-number":["PI18\/0358"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008799","name":"Gilead Foundation","doi-asserted-by":"publisher","award":["IN-ES-987-5349"],"award-info":[{"award-number":["IN-ES-987-5349"]}],"id":[{"id":"10.13039\/100008799","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008318","name":"Asociaci\u00f3n Espa\u00f1ola para el Estudio del H\u00edgado","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008318","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Societat Catalana Digestologia"},{"DOI":"10.13039\/100031015","name":"Hospital Cl\u00ednic de Barcelona","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100031015","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Bristol Myers Squibb and Celgene"},{"DOI":"10.13039\/501100009253","name":"European Association for the Study of the Liver","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009253","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002704","name":"Fundaci\u00f3n Cient\u00edfica Asociaci\u00f3n Espa\u00f1ola Contra el C\u00e1ncer","doi-asserted-by":"publisher","award":["PI044031"],"award-info":[{"award-number":["PI044031"]}],"id":[{"id":"10.13039\/501100002704","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"DOI":"10.1186\/s12876-025-03611-w","type":"journal-article","created":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T16:11:56Z","timestamp":1738599116000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Liver cancer risk and changes in lifestyle habits after successful hepatitis C virus therapy post-DAA HCV therapy: lifestyle changes and liver cancer risk"],"prefix":"10.1186","volume":"25","author":[{"given":"N\u00faria","family":"Granel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gemma","family":"Iserte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Concepci\u00f3","family":"Bartres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neus","family":"Llarch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Pla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V\u00edctor","family":"Sapena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zoe","family":"Mari\u00f1o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabela","family":"Lens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ram\u00f3n","family":"Vilana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabel","family":"Nu\u00f1ez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Darnell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ernest","family":"Belmonte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1ngeles","family":"Garc\u00eda-Criado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alba","family":"D\u00edaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Sanduzzi-Zamparelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carla","family":"Fuster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergio","family":"Mu\u00f1oz-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Ayuso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordi","family":"Rimola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandro","family":"Forner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandre","family":"Soler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ferran","family":"Torres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9","family":"R\u00edos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordi","family":"Bruix","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew M.","family":"Moon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xavier","family":"Forns","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda","family":"Reig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,2,3]]},"reference":[{"key":"3611_CR1","unstructured":"World Health Organisation (WHO). Accelerating access to Hepatitis C diagnostics and treatment: Overcoming barriers in low-and middle-income countries: Global Progress Report 2020. 2021."},{"key":"3611_CR2","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1016\/S0140-6736(19)32320-7","volume":"394","author":"CW Spearman","year":"2019","unstructured":"Spearman CW, Dusheiko GM, Hellard M, Sonderup M, Hepatitis C, Lancet. (London England). 2019;394:1451\u201366. https:\/\/doi.org\/10.1016\/S0140-6736(19)32320-7.","journal-title":"(London England)"},{"key":"3611_CR3","doi-asserted-by":"publisher","first-page":"329","DOI":"10.7326\/0003-4819-158-5-201303050-00005","volume":"158","author":"RL Morgan","year":"2013","unstructured":"Morgan RL, Baack B, Smith BD, Yartel A, Pitasi M, Falck-Ytter Y. Eradication of Hepatitis C virus infection and the development of hepatocellular carcinoma. Ann Intern Med. 2013;158:329. https:\/\/doi.org\/10.7326\/0003-4819-158-5-201303050-00005.","journal-title":"Ann Intern Med"},{"key":"3611_CR4","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.jhep.2016.10.017","volume":"66","author":"AJ Van der Meer","year":"2017","unstructured":"Van der Meer AJ, Feld JJ, Hofer H, Almasio PL, Calvaruso V, Fern\u00e1ndez-Rodr\u00edguez CM, et al. Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication. J Hepatol. 2017;66:485\u201393. https:\/\/doi.org\/10.1016\/j.jhep.2016.10.017.","journal-title":"J Hepatol"},{"key":"3611_CR5","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.jhep.2016.01.034","volume":"64","author":"S Bruno","year":"2016","unstructured":"Bruno S, Di Marco V, Iavarone M, Roffi L, Crosignani A, Calvaruso V, et al. Survival of patients with HCV cirrhosis and sustained virologic response is similar to the general population. J Hepatol. 2016;64:1217\u201323. https:\/\/doi.org\/10.1016\/j.jhep.2016.01.034.","journal-title":"J Hepatol"},{"key":"3611_CR6","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1053\/j.gastro.2019.07.033","volume":"157","author":"GN Ioannou","year":"2019","unstructured":"Ioannou GN, Beste LA, Green PK, Singal AG, Tapper EB, Waljee AK, et al. Increased risk for hepatocellular carcinoma persists up to 10 years after HCV eradication in patients with baseline cirrhosis or high FIB-4 scores. Gastroenterology. 2019;157:1264\u2013e12784. https:\/\/doi.org\/10.1053\/j.gastro.2019.07.033.","journal-title":"Gastroenterology"},{"key":"3611_CR7","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1053\/j.gastro.2017.06.012","volume":"153","author":"F Kanwal","year":"2017","unstructured":"Kanwal F, Kramer J, Asch SM, Chayanupatkul M, Cao Y, El-Serag HB. Risk of hepatocellular cancer in HCV patients treated with direct-acting antiviral agents. Gastroenterology. 2017;153:996\u2013e10051. https:\/\/doi.org\/10.1053\/j.gastro.2017.06.012.","journal-title":"Gastroenterology"},{"key":"3611_CR8","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1002\/hep.30823","volume":"71","author":"F Kanwal","year":"2020","unstructured":"Kanwal F, Kramer JR, Asch SM, Cao Y, Li L, El-Serag HB. Long\u2010term risk of hepatocellular carcinoma in HCV patients treated with direct acting antiviral agents. Hepatology. 2020;71:44\u201355. https:\/\/doi.org\/10.1002\/hep.30823.","journal-title":"Hepatology"},{"key":"3611_CR9","doi-asserted-by":"publisher","unstructured":"Sanduzzi-Zamparelli M, Mari\u00f1o Z, Lens S, Sapena V, Iserte G, Pla A, et al. Liver cancer risk after HCV cure in patients with advanced liver disease without non-characterized nodules. J Hepatol. 2021;29. https:\/\/doi.org\/10.1016\/j.jhep.2021.11.023. S0168-8278(21)02228-5.","DOI":"10.1016\/j.jhep.2021.11.023"},{"key":"3611_CR10","doi-asserted-by":"publisher","unstructured":"Semmler G, Meyer EL, Kozbial K, Schwabl P, Hametner-Schreil S, Zanetto A, et al. HCC risk stratification after cure of hepatitis C in patients with compensated advanced chronic liver disease. J Hepatol. 2021;3. https:\/\/doi.org\/10.1016\/J.JHEP.2021.11.025. S0168-8278(21)02234-0.","DOI":"10.1016\/J.JHEP.2021.11.025"},{"key":"3611_CR11","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/J.JHEP.2021.09.013","volume":"76","author":"R D\u2019Ambrosio","year":"2022","unstructured":"D\u2019Ambrosio R, Degasperi E, Anolli MP, Fanetti I, Borghi M, Soffredini R, et al. Incidence of liver- and non-liver-related outcomes in patients with HCV-cirrhosis after SVR. J Hepatol. 2022;76:302\u201310. https:\/\/doi.org\/10.1016\/J.JHEP.2021.09.013.","journal-title":"J Hepatol"},{"key":"3611_CR12","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.jhep.2023.03.017","volume":"79","author":"H Devarbhavi","year":"2023","unstructured":"Devarbhavi H, Asrani SK, Arab JP, Nartey YA, Pose E, Kamath PS. Global burden of liver disease: 2023 update. J Hepatol. 2023;79:516\u201337. https:\/\/doi.org\/10.1016\/j.jhep.2023.03.017.","journal-title":"J Hepatol"},{"key":"3611_CR13","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1136\/gutjnl-2019-319720","volume":"69","author":"MA Avila","year":"2020","unstructured":"Avila MA, Dufour J-F, Gerbes AL, Zoulim F, Bataller R, Burra P, et al. Recent advances in alcohol-related liver disease (ALD): summary of a gut round table meeting. Gut. 2020;69:764\u201380. https:\/\/doi.org\/10.1136\/gutjnl-2019-319720.","journal-title":"Gut"},{"key":"3611_CR14","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/j.jhep.2016.06.018","volume":"65","author":"E Stein","year":"2016","unstructured":"Stein E, Cruz-Lemini M, Altamirano J, Ndugga N, Couper D, Abraldes JG, et al. Heavy daily alcohol intake at the population level predicts the weight of alcohol in cirrhosis burden worldwide. J Hepatol. 2016;65:998\u20131005. https:\/\/doi.org\/10.1016\/j.jhep.2016.06.018.","journal-title":"J Hepatol"},{"key":"3611_CR15","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","volume":"15","author":"Z Younossi","year":"2018","unstructured":"Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15:11\u201320. https:\/\/doi.org\/10.1038\/nrgastro.2017.109.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"3611_CR16","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/j.jhep.2018.05.036","volume":"69","author":"C Estes","year":"2018","unstructured":"Estes C, Anstee QM, Arias-Loste MT, Bantel H, Bellentani S, Caballeria J, et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016\u20132030. J Hepatol. 2018;69:896\u2013904. https:\/\/doi.org\/10.1016\/j.jhep.2018.05.036.","journal-title":"J Hepatol"},{"key":"3611_CR17","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1002\/hep.29466","volume":"67","author":"C Estes","year":"2018","unstructured":"Estes C, Razavi H, Loomba R, Younossi Z, Sanyal AJ. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology. 2018;67:123\u201333. https:\/\/doi.org\/10.1002\/hep.29466.","journal-title":"Hepatology"},{"key":"3611_CR18","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.1007\/s10620-020-06457-2","volume":"66","author":"JN Benhammou","year":"2021","unstructured":"Benhammou JN, Moon AM, Pisegna JR, Su F, Vutien P, Moylan CA, et al. Nonalcoholic fatty liver disease risk factors affect liver-related outcomes after direct-acting antiviral treatment for Hepatitis C. Dig Dis Sci. 2021;66:2394\u2013406. https:\/\/doi.org\/10.1007\/s10620-020-06457-2.","journal-title":"Dig Dis Sci"},{"key":"3611_CR19","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1002\/hep4.1464","volume":"4","author":"NJ Kim","year":"2020","unstructured":"Kim NJ, Pearson M, Vutien P, Su F, Moon AM, Berry K, et al. Alcohol Use and Long-Term outcomes among U.S. Veterans who received Direct\u2010Acting antivirals for Hepatitis C treatment. Hepatol Commun. 2020;4:314\u201324. https:\/\/doi.org\/10.1002\/hep4.1464.","journal-title":"Hepatol Commun"},{"key":"3611_CR20","doi-asserted-by":"publisher","DOI":"10.15403\/jgld-805","author":"A Bhurwal","year":"2020","unstructured":"Bhurwal A, Ratta P, Yoshitake S, Pioppo L, Reja D, Dellatore P, et al. Inverse Association of Coffee with Liver Cancer Development: an updated systematic review and Meta-analysis. J Gastrointest Liver Dis. 2020. https:\/\/doi.org\/10.15403\/jgld-805.","journal-title":"J Gastrointest Liver Dis"},{"key":"3611_CR21","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1007\/s00535-023-02060-0","volume":"59","author":"T Kawaguchi","year":"2024","unstructured":"Kawaguchi T, Kawaguchi A, Hashida R, Nakano D, Tsutsumi T, Kawaguchi M, et al. Resistance exercise in combination with aerobic exercise reduces the incidence of serious events in patients with liver cirrhosis: a meta-analysis of randomized controlled trials. J Gastroenterol. 2024;59:216\u201328. https:\/\/doi.org\/10.1007\/s00535-023-02060-0.","journal-title":"J Gastroenterol"},{"key":"3611_CR22","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1111\/j.1360-0443.1993.tb02093.x","volume":"88","author":"JB SAUNDERS","year":"1993","unstructured":"SAUNDERS JB, AASLAND OG, BABOR TF, DE LA FUENTE JR GRANTM. Development of the Alcohol Use disorders Identification Test (AUDIT): WHO Collaborative Project on early detection of persons with harmful alcohol Consumption-II. Addiction. 1993;88:791\u2013804. https:\/\/doi.org\/10.1111\/j.1360-0443.1993.tb02093.x.","journal-title":"Addiction"},{"key":"3611_CR23","unstructured":"Babor TF, Higgins-Biddle JC, Saunders JB, Monteriro MG. AUDIT. The Alcohol Use disorders Identification Test. World Heal Organ; 2001."},{"key":"3611_CR24","doi-asserted-by":"publisher","DOI":"10.1002\/9780470316696","volume-title":"Multiple imputation for nonresponse in surveys. Hoboken, NJ","author":"DB Rubin","year":"1987","unstructured":"Rubin DB. Multiple imputation for nonresponse in surveys. Hoboken, NJ. USA: John Wiley & Sons, Inc.; 1987. https:\/\/doi.org\/10.1002\/9780470316696."},{"key":"3611_CR25","doi-asserted-by":"publisher","DOI":"10.1002\/9780470510445","volume-title":"Missing Data in Clinical studies","author":"G Molenberghs","year":"2007","unstructured":"Molenberghs G, Kenward MG. Missing Data in Clinical studies. New York: Wiley; 2007. https:\/\/doi.org\/10.1002\/9780470510445."},{"key":"3611_CR26","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1080\/01621459.1948.10483284","volume":"43","author":"AH Bowker","year":"1948","unstructured":"Bowker AH. A test for Symmetry in Contingency tables. J Am Stat Assoc. 1948;43:572\u20134. https:\/\/doi.org\/10.1080\/01621459.1948.10483284.","journal-title":"J Am Stat Assoc"},{"key":"3611_CR27","unstructured":"World Health Organisation (WHO). Obesity and overweight. World Heal Organ; 2021."},{"key":"3611_CR28","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1056\/NEJMoa021423","volume":"348","author":"EE Calle","year":"2003","unstructured":"Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and Mortality from Cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003;348:1625\u201338. https:\/\/doi.org\/10.1056\/NEJMoa021423.","journal-title":"N Engl J Med"},{"key":"3611_CR29","doi-asserted-by":"publisher","first-page":"157","DOI":"10.3350\/cmh.2020.0176","volume":"27","author":"W Sohn","year":"2021","unstructured":"Sohn W, Lee HW, Lee S, Lim JH, Lee MW, Park CH, et al. Obesity and the risk of primary liver cancer: a systematic review and meta-analysis. Clin Mol Hepatol. 2021;27:157\u201374. https:\/\/doi.org\/10.3350\/cmh.2020.0176.","journal-title":"Clin Mol Hepatol"},{"key":"3611_CR30","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1097\/COC.0000000000000388","volume":"41","author":"A Gupta","year":"2018","unstructured":"Gupta A, Das A, Majumder K, Arora N, Mayo HG, Singh PP, et al. Obesity is independently Associated with increased risk of Hepatocellular Cancer\u2013related mortality. Am J Clin Oncol. 2018;41:874\u201381. https:\/\/doi.org\/10.1097\/COC.0000000000000388.","journal-title":"Am J Clin Oncol"},{"key":"3611_CR31","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1016\/j.jhep.2022.04.040","volume":"77","author":"K Staufer","year":"2022","unstructured":"Staufer K, Huber-Sch\u00f6nauer U, Strebinger G, Pimingstorfer P, Suesse S, Scherzer T-M, et al. Ethyl Glucuronide in hair detects a high rate of harmful alcohol consumption in presumed non-alcoholic fatty liver disease. J Hepatol. 2022;77:918\u201330. https:\/\/doi.org\/10.1016\/j.jhep.2022.04.040.","journal-title":"J Hepatol"},{"key":"3611_CR32","doi-asserted-by":"publisher","first-page":"352","DOI":"10.3390\/healthcare12030352","volume":"12","author":"HG Dailah","year":"2024","unstructured":"Dailah HG. The influence of nurse-led interventions on diseases Management in patients with diabetes Mellitus: a narrative review. Healthcare. 2024;12:352. https:\/\/doi.org\/10.3390\/healthcare12030352.","journal-title":"Healthcare"},{"key":"3611_CR33","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1177\/1078390319872536","volume":"26","author":"Y Gonzalez","year":"2020","unstructured":"Gonzalez Y, Kozachik SL, Hansen BR, Sanchez M, Finnell DS. Nurse-led delivery of brief interventions for At-Risk Alcohol Use: an integrative review. J Am Psychiatr Nurses Assoc. 2020;26:27\u201342. https:\/\/doi.org\/10.1177\/1078390319872536.","journal-title":"J Am Psychiatr Nurses Assoc"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-025-03611-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-025-03611-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-025-03611-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T16:12:12Z","timestamp":1738599132000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-025-03611-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,3]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3611"],"URL":"https:\/\/doi.org\/10.1186\/s12876-025-03611-w","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,3]]},"assertion":[{"value":"19 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All participants signed the informed consent for the study previously approved by the Research Ethics Committee of the Hospital Cl\u00ednic of Barcelona (HCB\/2015\/0752). Furthermore, the study was performed in accordance with the Declaration of Helsinki (Fortaleza, Brazil, October 2013). As specified in the informed consent form, data were collected from participants until revocation of it, death or completion 10 years after SVR.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"No applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"NG: received congress registration from Eisai; GI: received travel grants from Bayer; CB: none; NL: received consultancy fees from Bayer, Universal DX and AstraZeneca, speaker fees from Roche and AstraZeneca, travel funding from Bayer and congress registration from Eisai; AP: none; VS: received travel grants from Bayer and consultancy fees from LEO Pharma; SL: received consultancy and speaker fees from Gilead and Abbvie and grants from Gilead; ZM: received consultancy fees from Gilead, Abbvie, Alexion, Orphalan and Deep Genomics; speaker fees from Gilead, Abbvie and Orphalan. Research grants from Gilead; RV: none; IN: none; AD: received speaker fees and travel grants from Bayer; EB: none; AGC: received speaker fees from BTG and Terumo; AD: received speaker fees and travel grants from Bayer; MSZ: received speaker fees from Bayer and travel grants from Bayer, BTG, MSD-Eisai and Roche; CF: none; SMM: received speaker fees from Bayer and travel grants from Bayer, MDS and Eisai; CA: received speaker fees, travel and research grants from Bayer, BTG and Terumo; consultancy from Roche; LB: none; JR: has consulted for Roche and received speaker fees from Bayer and Roche and travel grants from Bayer; AS: none; AF: received lecture fees from Gilead, Boston Scientific, Roche, AstraZeneca and MSD; consultancy fees from AstraZeneca, Roche, SIRTEX, AB Exact Science, Taiho and Guerbert; FT: DSMB fees from Basiela Pharmaceutica International, ArchivelFarma, S.L, Daiichi-Sankyo Pharma Development, ArQule and Rovi; speaker fees from Bayer and educational and training fees from Janssen and Ferrer; JR: Novartis, Lilly, LETIPharma, Merck Sharp & Dohme de Espa\u00f1a, ViforFresenius, Astra Zeneca and Boehringer Ingelheim Boehringer Ingelheim lecture fees educational outside the submitted work; JB: has consulted for Arqule, Bayer-Shering Pharma, Novartis, BMS, BTG- Biocompatibles, Eisai, Kowa, Terumo, Gilead, Bio-Alliance, Roche, AbbVie, MSD, Sirtex, Ipsen, Astra-Medimmune, Incyte, Quirem, Adaptimmune, Lilly, Basilea, Nerviano, Sanofi; received research\/educational grants from Bayer; paid conferences from Bayer, BTG, AstraZeneca and Ipsen; andlecture fees from Bayer-Shering Pharma, BTG-Biocompatibles, Eisai, Terumo, Sirtex and Ipsen; AMM: Consultant for TARGET RWE; XF: acted as advisor for Gilead; MR: has served as a consultant or on advisory boards and\/or received travel support from Bayer, BMS, Roche, Ipsen, AstraZeneca, Eisai, Geneos Therapeutics, UniveralDx, MSD and Lilly, lecture fees from Bayer, BMS, Gilead, AstraZeneca, ROCHE and Lilly and Institutional research grants from Bayer and Ipsen.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"51"}}